Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
28 févr. 2024 08h00 HE
|
Protara Therapeutics
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics to Participate in Upcoming Investor Conferences
31 janv. 2024 07h30 HE
|
Protara Therapeutics
NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology
30 nov. 2023 08h30 HE
|
Protara Therapeutics
New results from six patients with HGTa papillary tumors show five of six patients with HGRFS at Week 12Data continue to support favorable tolerability of TARA-002 in patients with NMIBCAs previously...
Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
03 nov. 2023 08h00 HE
|
Protara Therapeutics
Dosing is progressing well in ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expected in 1H24Company initiated ADVANCED-2 trial evaluating TARA-002 in NMIBC...
Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
23 oct. 2023 08h00 HE
|
Protara Therapeutics
NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ
20 sept. 2023 08h30 HE
|
Protara Therapeutics
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
05 sept. 2023 07h30 HE
|
Protara Therapeutics
NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update
03 août 2023 08h00 HE
|
Protara Therapeutics
Dosing is progressing on schedule in ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS; preliminary results expected in 1H24Company plans to commence dosing in ADVANCED-2 trial...
Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in Situ
15 mai 2023 08h00 HE
|
Protara Therapeutics
Dosing of first patients follows recent presentation of positive preliminary data from Phase 1a dose escalation portion of ADVANCED-1 trialCompany advancing NMIBC clinical development program, with...
Protara Therapeutics Announces First Quarter 2023 Financial Results and Business Update
04 mai 2023 08h00 HE
|
Protara Therapeutics
Favorable tolerability and anti-tumor activity observed in NMIBC patients treated with TARA-002 in ADVANCED-1 trialCompany plans to initiate ADVANCED-2 trial in BCG-naïve CIS patients and...